Opinion
Video
Author(s):
An MDS specialist discusses cytopenias associated with imetelstat treatment in patients with lower-risk MDS, highlighting findings from the IMerge clinical trial.
Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL
Camidge and Cooper on Finding Purpose and Embracing Nuance in Hospital Chaplaincy
FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD
Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC
Odronextamab Elicits Durable Responses in Heavily Pretreated R/R Follicular Lymphoma
Brentuximab Vedotin Triplet Improves Survival Over R2 Across Key R/R DLBCL Subgroups
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC